Abstract: A method for determining test evaluation information includes: building a hardware-in-the-loop test environment, wherein the hardware-in-the-loop test environment comprises a cloud control platform under test, a road traffic scenario simulation platform, and a real-time simulator, and wherein the road traffic scenario simulation platform is configured to build a variety of road traffic scenarios, the real-time simulator is configured to realize communication between the cloud control platform under test and respective interface boards; determining a test scenario according to a function to be realized by the cloud control platform under test; performing a test operation on the cloud control platform under test based on the hardware-in-the-loop test environment and the test scenario, and collecting functional parameters of the cloud control platform under test; and determining test evaluation information of the cloud control platform under test based on the functional parameters.

Abstract: The present application provides a method and device for merging a vehicle from a branch road into a main road, an electronic device, and a storage medium, which relates to a technical field of unmanned driving. The method for merging the vehicle from the branch road into the main road includes: acquiring vehicle information of the vehicle to be merged from the branch road into the main road; acquiring traffic flow information of an outer lane of the main road within a preset range of a junction; controlling the vehicle to be merged into the main road to merge into the main road according to the preset rules based on the traffic flow information of the outer lane of the main road and the vehicle information of the vehicle to be merged into the main road.

Abstract: The application provides a method, device, electronic device for vehicle cooperative decision-making as well as a computer storage medium. The method for vehicle cooperative decision-making applied at a cloud server includes: receiving a cooperative decision request sent by a roadside device, wherein the cooperative decision request is a request sent by the roadside device after it is recognized that a road is congested based on acquired real-time road information; acquiring information of a road scene included in the cooperative decision request; determining a congestion scene type based on the information of the road scene; calculating multi-vehicle oriented decision planning schemes using a preset scene cooperative decision model based on the congestion scene type; and sending the decision planning schemes to respective vehicles, so that the vehicles perform respective driving operations according to the decision planning schemes.

Abstract: The present application discloses an edge cloud system, a server, and a cloud control platform. The edge cloud system includes: an edge cloud access gateway module configured to access data of the road side terminal, the vehicle terminal, the third party platform and the regional cloud; a standardized hierarchical sharing interface module connected to the edge cloud access gateway module, wherein the standardized hierarchical sharing interface module is configured to standardize and classify the data of the road side terminal, the vehicle terminal, the third party platform and the regional cloud accessed by the edge cloud access gateway module to form multiple levels of standardized data; wherein standardized data at each level of the multiple levels of standardized data is available to be called only by a module with corresponding level of that of the standardized data.

Abstract: Provided herein is a method of producing peptide nanoparticles comprising vortex-mixing (a) a hydrophobic or amphiphilic peptide or peptide conjugate, (b) one or more lipids that are free of a water-soluble polymer, (c) one or more lipids covalently attached to a water-soluble polymer, and (d) a hydrophilic solvent, to provide peptide nanoparticles.

Abstract: The present disclosure provides peptides that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, particularly nanoparticle compositions, comprising the same and to methods of using the peptides to treat atherosclerosis, thrombosis, stroke, heart attack, inflammation, acute respiratory distress syndrome (ARDS), autoimmune diseases, AV Fistula for hemodialysis or organ transplantation.

Abstract: The embodiments of the application provide an image super-resolution reconstruction method and device featuring labeled data sharpening. The method comprises: establishing a deep neural network for image reconstruction from low resolution to high resolution, obtaining low-resolution sample data by sub-sampling and Sobel operator calculation, and then sharpening labeled data to a certain extent so that edges of the labeled data are clearer and object features are easier to see. A model is obtained by training the deep neural network, and the model is used to perform super-resolution processing on the image to obtain an image with a higher resolution. The obtained image has a clear texture, the resolution and definition are significantly improved, and the quality evaluation indexes of the image are better.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Methods and compositions for inhibition of platelet cell aggregation are described. In particular, compositions comprising cell permeant RGT peptides, such as RGT bound to a lipid moiety are provided. Compositions may be used in the treatment and prevention of clot related diseases such as stroke and myocardial infarction.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIb? fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit intracellular function of 14-3-3.

Abstract: Methods and compositions for inhibition of platelet cell aggregation are described. In particular, compositions comprising cell permeant RGT peptides, such as RGT bound to a lipid moiety are provided. Compositions may be used in the treatment and prevention of clot related diseases such as stroke and myocardial infarction.

Abstract: The present invention is directed to compositions comprising inhibitors of GPIb-IX-VWF binding and methods of treating or preventing thrombosis associated with sepsis or endotoxemia in a mammal.